|
US5314995A
(en)
*
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
US5349053A
(en)
*
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
WO1992000763A1
(en)
*
|
1990-07-03 |
1992-01-23 |
Akzo N.V. |
Immunoreactive compound
|
|
JP3105629B2
(ja)
*
|
1991-04-23 |
2000-11-06 |
サングスタット メディカル コーポレイション |
特異的結合ペアのメンバーの細胞活性調節接合体
|
|
US5635599A
(en)
*
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
CA2196200A1
(en)
*
|
1994-07-29 |
1996-02-15 |
Michael Joseph Browne |
Novel compounds
|
|
US7597886B2
(en)
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7820798B2
(en)
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
ATE255910T1
(de)
*
|
1996-04-10 |
2003-12-15 |
Sangstat Medical Corp |
Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
|
|
ATE490980T1
(de)
|
1998-03-19 |
2010-12-15 |
Human Genome Sciences |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
EP1118334A1
(en)
*
|
2000-01-11 |
2001-07-25 |
Aventis Behring Gesellschaft mit beschränkter Haftung |
Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
|
|
EP1118335A1
(en)
*
|
2000-01-11 |
2001-07-25 |
Aventis Behring GmbH |
Method for the production of conjugates for the treatment of allergic reactions and autoimmune diseases
|
|
CN102805868A
(zh)
|
2000-03-31 |
2012-12-05 |
普渡研究基金会 |
用配体-免疫原缀合物治疗的方法
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
DE60143798D1
(de)
|
2000-06-16 |
2011-02-17 |
Cambridge Antibody Tech |
Immunspezifisch bindende antikörper gegen blys
|
|
EP2412384A1
(en)
|
2000-11-28 |
2012-02-01 |
MedImmune, LLC |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
|
WO2002083704A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
JP4309758B2
(ja)
|
2001-05-25 |
2009-08-05 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
Trailレセプターに免疫特異的に結合する抗体
|
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
|
EP2270049A3
(en)
|
2002-04-12 |
2011-03-09 |
Medimmune, Inc. |
Recombinant anti-interleukin-9-antibody
|
|
ES2377720T3
(es)
|
2002-05-10 |
2012-03-30 |
Purdue Research Foundation |
Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
|
MXPA05003884A
(es)
|
2002-10-16 |
2005-10-05 |
Euro Celtique Sa |
Anticuerpos que enlazan polipeptidos ca 125/0772p a celulas asociadas y metodos de uso de los mismos.
|
|
JP2006518997A
(ja)
|
2003-01-21 |
2006-08-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規アシルコエンザイムa:モノアシルグリセロールアシルトランスフェラーゼ−3(mgat3)をコードするポリヌクレオチドおよびその用途
|
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
|
EP1613273B1
(en)
|
2003-04-11 |
2012-06-13 |
MedImmune, LLC |
Recombinant il-9 antibodies and uses thereof
|
|
EP1660186B1
(en)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanization of antibodies
|
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
|
US7973139B2
(en)
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
EP2422811A2
(en)
|
2004-10-27 |
2012-02-29 |
MedImmune, LLC |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
EP1869192B1
(en)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
|
CN101203241B
(zh)
|
2005-04-19 |
2012-02-22 |
西雅图基因公司 |
人源化抗-cd70结合物和其应用
|
|
KR101446989B1
(ko)
|
2005-05-06 |
2014-10-15 |
지모제넥틱스, 인코포레이티드 |
Il-31 단클론성 항체 및 사용법
|
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
WO2007008604A2
(en)
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
|
EP1945261A4
(en)
|
2005-11-07 |
2010-05-12 |
Scripps Research Inst |
COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
|
|
CA2650730A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
|
RU2009111884A
(ru)
|
2006-09-01 |
2010-10-10 |
Займоджинетикс, Инк. (Us) |
Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
|
|
EP2407548A1
(en)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Molecules with reduced half-lives, compositions and uses thereof
|
|
DK2099823T4
(da)
|
2006-12-01 |
2022-05-09 |
Seagen Inc |
Målbindingsmiddelvarianter og anvendelser deraf
|
|
AU2008232903B9
(en)
|
2007-03-30 |
2013-09-05 |
Medimmune Llc |
Antibodies with decreased deamidation profiles
|
|
ES2540807T3
(es)
|
2007-05-04 |
2015-07-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
|
|
HUE026728T2
(en)
|
2007-05-14 |
2016-06-28 |
Medimmune Llc |
A method for reducing eosinophil levels
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
LT2796466T
(lt)
|
2007-12-07 |
2018-02-26 |
Zymogenetics, Inc. |
Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
|
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
|
ES2458541T5
(en)
|
2008-05-02 |
2025-08-04 |
Seagen Inc |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
US20120134984A1
(en)
|
2009-06-01 |
2012-05-31 |
Olga Lubman |
Molecules with extended half-lives and uses thereof
|
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
|
LT2769737T
(lt)
|
2009-07-20 |
2017-06-26 |
Bristol-Myers Squibb Company |
Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
|
|
EP2464657B1
(en)
|
2009-08-10 |
2015-04-01 |
MorphoSys AG |
Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
|
|
US8840889B2
(en)
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
ES2553440T3
(es)
|
2009-08-13 |
2015-12-09 |
Crucell Holland B.V. |
Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
EA201291180A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
|
PH12012502193A1
(en)
|
2010-05-06 |
2021-08-09 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
TWI627964B
(zh)
|
2010-07-09 |
2018-07-01 |
傑森疫苗防護公司 |
抗-人類呼吸道融合性病毒(rsv)抗體及其使用方法
|
|
SG10201913700SA
(en)
|
2010-07-09 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Factor ix polypeptides and methods of use thereof
|
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
|
PL2606070T3
(pl)
|
2010-08-20 |
2017-06-30 |
Novartis Ag |
Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
|
|
CA2809369A1
(en)
|
2010-08-27 |
2012-03-01 |
Stem Centrx, Inc. |
Notum protein modulators and methods of use
|
|
BR112013005116A2
(pt)
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
moduladores e métodos de uso
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
MX356400B
(es)
|
2010-12-08 |
2018-05-28 |
Abbvie Stemcentrx Llc |
Moduladores novedosos y metodos de uso.
|
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
US20150044208A1
(en)
|
2011-09-23 |
2015-02-12 |
Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa |
Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
|
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
|
SG11201401717VA
(en)
|
2011-11-04 |
2014-05-29 |
Novartis Ag |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
US9453073B2
(en)
|
2011-12-02 |
2016-09-27 |
Eli Lilly And Company |
Anti-glucagon antibodies and uses thereof
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
US20130273029A1
(en)
|
2011-12-05 |
2013-10-17 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
PE20150159A1
(es)
|
2011-12-21 |
2015-02-08 |
Novartis Ag |
Composiciones y metodos para anticuerpos que actuan sobre el factor p
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
KR102099073B1
(ko)
|
2012-02-24 |
2020-04-10 |
애브비 스템센트알엑스 엘엘씨 |
항 sez6 항체들 및 사용 방법
|
|
EP3093294A1
(en)
|
2012-02-24 |
2016-11-16 |
Stemcentrx, Inc. |
Dll3 modulators and methods of use
|
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
RU2681730C2
(ru)
|
2012-07-25 |
2019-03-12 |
Селлдекс Терапьютикс Инк. |
Антитела против kit и их применения
|
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
HUE053669T2
(hu)
|
2012-12-05 |
2021-07-28 |
Novartis Ag |
Készítmények és eljárások EPO-t célzó antitestekre
|
|
MX2015007931A
(es)
|
2012-12-18 |
2015-10-05 |
Novartis Ag |
Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
|
|
RU2019109456A
(ru)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
|
SMT201700530T1
(it)
|
2013-03-14 |
2018-01-11 |
Bristol Myers Squibb Co |
Combinazione di agonista di dr5 e antagonista anti-pd-1 e metodi d'uso
|
|
JP6824735B2
(ja)
|
2013-06-06 |
2021-02-03 |
ピエール、ファーブル、メディカマン |
抗C10orf54抗体およびその使用方法
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
|
US9475874B2
(en)
|
2013-08-26 |
2016-10-25 |
MabVax Therapeutics, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
|
WO2015031698A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Site-specific antibody conjugation methods and compositions
|
|
JP2016538318A
(ja)
|
2013-08-28 |
2016-12-08 |
ステムセントリックス, インコーポレイテッド |
新規sez6モジュレーターおよび使用方法
|
|
WO2015065954A1
(en)
|
2013-11-04 |
2015-05-07 |
Pfizer, Inc. |
Anti-efna4 antibody-drug conjugates
|
|
AU2015209131B2
(en)
|
2014-01-24 |
2020-06-25 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
AU2015240599B2
(en)
|
2014-04-04 |
2020-11-19 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
|
WO2015175375A1
(en)
|
2014-05-13 |
2015-11-19 |
Short Jay M |
Conditionally active biological proteins
|
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
|
CA2950602C
(en)
|
2014-06-04 |
2021-07-20 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
|
PT3177642T
(pt)
|
2014-08-07 |
2022-02-14 |
Novartis Ag |
Anticorpos semelhantes a angiopoietina 4 e métodos de uso
|
|
KR20170044115A
(ko)
|
2014-09-03 |
2017-04-24 |
바이오아트라, 엘엘씨 |
동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CA2970352A1
(en)
|
2014-12-11 |
2016-06-16 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
AU2016222830B2
(en)
|
2015-02-24 |
2021-02-25 |
Bioatla Llc |
Conditionally active biological proteins
|
|
HRP20230046T1
(hr)
|
2015-03-03 |
2023-03-03 |
Kymab Limited |
Protutijela, upotreba i postupci
|
|
CN107614526A
(zh)
|
2015-06-05 |
2018-01-19 |
诺华股份有限公司 |
靶向骨形成蛋白9(bmp9)的抗体及其方法
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
RU2752530C2
(ru)
|
2015-08-03 |
2021-07-29 |
Новартис Аг |
Способы лечения расстройств, связанных с fgf21
|
|
PT3347377T
(pt)
|
2015-09-09 |
2021-04-30 |
Novartis Ag |
Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
|
|
AU2016320748B2
(en)
|
2015-09-09 |
2019-05-02 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
|
|
HK1251158A1
(zh)
|
2015-09-29 |
2019-01-25 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
MX2018005063A
(es)
|
2015-11-02 |
2018-12-10 |
Bioatla Llc |
Polipéptidos condicionalmente activos.
|
|
EP3383891A1
(en)
|
2015-12-04 |
2018-10-10 |
Novartis AG |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
EP3432925A4
(en)
|
2016-03-22 |
2019-11-06 |
Bionomics Limited |
ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
|
|
CN109071647B
(zh)
|
2016-04-27 |
2022-11-22 |
诺华股份有限公司 |
抗生长分化因子15的抗体及其用途
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
|
EP3481866B1
(en)
|
2016-07-06 |
2024-07-24 |
Bristol-Myers Squibb Company |
Combination of tim-4 antagonist and pd-1 antagonist and methods of use
|
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
|
AU2017329024A1
(en)
|
2016-09-19 |
2019-03-21 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
KR102702288B1
(ko)
|
2016-12-23 |
2024-09-05 |
노파르티스 아게 |
항-인자 XI/XIa 항체를 사용한 치료 방법
|
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
|
WO2018146594A1
(en)
|
2017-02-08 |
2018-08-16 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
IL322309A
(en)
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EP3694889A1
(en)
|
2017-10-13 |
2020-08-19 |
Boehringer Ingelheim International GmbH |
Human antibodies to thomsen-nouvelle (tn) antigen
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
|
JP7438953B2
(ja)
|
2018-02-01 |
2024-02-27 |
イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド |
完全ヒト化抗b細胞成熟抗原(bcma)の単鎖抗体およびその応用
|
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
KR20250151605A
(ko)
|
2018-06-01 |
2025-10-21 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
|
PE20211491A1
(es)
|
2018-09-27 |
2021-08-11 |
Celgene Corp |
PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CN113874392B
(zh)
|
2019-03-28 |
2025-10-21 |
丹尼斯科美国公司 |
工程化抗体
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
TWI905099B
(zh)
|
2019-05-21 |
2025-11-21 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TWI877278B
(zh)
|
2019-12-30 |
2025-03-21 |
美商思進公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
|
EP4143224A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Immunoglobulin variants
|
|
WO2021220215A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Engineered immunoglobulins
|
|
TW202212354A
(zh)
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
EP4271482A2
(en)
|
2020-12-31 |
2023-11-08 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
|
AU2022304582A1
(en)
|
2021-06-29 |
2024-02-01 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
|
JP2025501461A
(ja)
|
2021-12-07 |
2025-01-22 |
イノベント バイオロジクス(スーチョウ)カンパニー,リミティド |
Bcmaに結合する抗体およびその使用
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
EP4514846A1
(en)
|
2022-04-26 |
2025-03-05 |
Novartis AG |
Multispecific antibodies targeting il-13 and il-18
|
|
EP4554619A1
(en)
|
2022-07-15 |
2025-05-21 |
Danisco US Inc. |
Methods for producing monoclonal antibodies
|
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
CN118725113A
(zh)
|
2023-03-28 |
2024-10-01 |
三优生物医药(上海)有限公司 |
一种靶向cd3的抗体或其抗原结合片段及其用途
|
|
WO2025104604A1
(en)
|
2023-11-14 |
2025-05-22 |
Janssen Pharmaceuticals, Inc. |
Anti-respiratory syncytial virus antibodies and uses thereof
|